{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T02:45:32Z","timestamp":1791081932889,"version":"4.1.0"},"reference-count":85,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100006919","name":"Massachusetts Institute of Technology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006919","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013136","name":"Office of Sex Offender Sentencing, Monitoring, Apprehending, Registering, and Tracking","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013136","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001348","name":"Agency for Science, Technology and Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001348","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001381","name":"National Research Foundation Singapore","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001381","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Trends in Cancer"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.trecan.2026.01.007","type":"journal-article","created":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T00:25:52Z","timestamp":1774484752000},"page":"434-446","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["In vivo CAR T cell engineering: design principles and open questions"],"prefix":"10.1016","volume":"12","author":[{"given":"Amin","family":"Aalipour","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariana","family":"Barreiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Garmilla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2281-3518","authenticated-orcid":false,"given":"Michael E.","family":"Birnbaum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.trecan.2026.01.007_bb0005","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1056\/NEJMra1706169","article-title":"Chimeric antigen receptor therapy","volume":"379","author":"June","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.trecan.2026.01.007_bb0010","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/s41571-023-00754-1","article-title":"Long-term outcomes following CAR T cell therapy: what we know so far","volume":"20","author":"Cappell","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.trecan.2026.01.007_bb0015","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20230903","article-title":"CAR-T cell manufacturing: major process parameters and next-generation strategies","volume":"221","author":"Ayala Ceja","year":"2024","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.trecan.2026.01.007_bb0020","doi-asserted-by":"crossref","first-page":"e57","DOI":"10.1016\/S2352-3026(24)00273-4","article-title":"Accelerating and optimising CAR T-cell manufacture to deliver better patient products","volume":"12","author":"Agliardi","year":"2025","journal-title":"Lancet Haematol."},{"key":"10.1016\/j.trecan.2026.01.007_bb0025","doi-asserted-by":"crossref","first-page":"2663","DOI":"10.1182\/bloodadvances.2024013656","article-title":"Impact of vein-to-vein time in patients with R\/R LBCL treated with axicabtagene ciloleucel","volume":"9","author":"Locke","year":"2025","journal-title":"Blood Adv."},{"key":"10.1016\/j.trecan.2026.01.007_bb0030","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1038\/s41571-022-00607-3","article-title":"Preparing for CAR T cell therapy: patient selection, bridging therapies and lymphodepletion","volume":"19","author":"Amini","year":"2022","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.trecan.2026.01.007_bb0035","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1182\/bloodadvances.2023011992","article-title":"Early predictive factors of failure in autologous CAR T-cell manufacturing and\/or efficacy in hematologic malignancies","volume":"8","author":"Baguet","year":"2024","journal-title":"Blood Adv."},{"key":"10.1016\/j.trecan.2026.01.007_bb0040","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1038\/s41551-021-00842-6","article-title":"Rapid manufacturing of non-activated potent CAR T cells","volume":"6","author":"Ghassemi","year":"2022","journal-title":"Nat. Biomed. Eng."},{"key":"10.1016\/j.trecan.2026.01.007_bb0045","doi-asserted-by":"crossref","DOI":"10.1172\/JCI150807","article-title":"CAR T cell manufacturing from naive\/stem memory T lymphocytes enhances antitumor responses while curtailing cytokine release syndrome","volume":"132","author":"Arcangeli","year":"2022","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.trecan.2026.01.007_bb0050","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1303935","article-title":"Lymphodepletion\u2014an essential but undervalued part of the chimeric antigen receptor T-cell therapy cycle","volume":"14","author":"Lickefett","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.trecan.2026.01.007_bb0055","doi-asserted-by":"crossref","first-page":"4442","DOI":"10.1158\/1078-0432.CCR-20-0305","article-title":"The role of antigen spreading in the efficacy of immunotherapies","volume":"26","author":"Brossart","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.trecan.2026.01.007_bb0060","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1182\/blood.2023022717","article-title":"B-cell\u2013directed CAR T-cell therapy activates CD8+cytotoxic CARneg bystander T cells in patients and nonhuman primates","volume":"144","author":"Kaminski","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.trecan.2026.01.007_bb0065","article-title":"In vivo chimeric antigen receptor (CAR)-T cell therapy","author":"Bot","year":"2025","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.trecan.2026.01.007_bb0070","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1038\/s41577-025-01174-1","article-title":"In vivo CAR engineering for immunotherapy","volume":"25","author":"Li","year":"2025","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.trecan.2026.01.007_bb0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2024.105266","article-title":"Advancements and challenges in developing in vivo CAR T cell therapies for cancer treatment","volume":"106","author":"Bui","year":"2024","journal-title":"eBioMedicine"},{"key":"10.1016\/j.trecan.2026.01.007_bb0080","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2025.105834","article-title":"Viral and non-viral vectors in gene therapy: current state and clinical perspectives","volume":"118","author":"Geng","year":"2025","journal-title":"eBioMedicine"},{"key":"10.1016\/j.trecan.2026.01.007_bb0085","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/s41392-021-00487-6","article-title":"Viral vector platforms within the gene therapy landscape","volume":"6","author":"Bulcha","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.trecan.2026.01.007_bb0090","doi-asserted-by":"crossref","first-page":"7306","DOI":"10.1073\/pnas.1214441110","article-title":"LDL receptor and its family members serve as the cellular receptors for vesicular stomatitis virus","volume":"110","author":"Finkelshtein","year":"2013","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.trecan.2026.01.007_bb0095","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1005641","article-title":"Receptor-targeted nipah virus glycoproteins improve cell-type selective gene delivery and reveal a preference for membrane-proximal cell attachment","volume":"12","author":"Bender","year":"2016","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.trecan.2026.01.007_bb0100","doi-asserted-by":"crossref","first-page":"3210","DOI":"10.1038\/s41596-021-00510-8","article-title":"Genetic in vivo engineering of human T lymphocytes in mouse models","volume":"16","author":"Weidner","year":"2021","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.trecan.2026.01.007_bb0105","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.4049\/jimmunol.1500956","article-title":"Exclusive transduction of human CD4+T cells upon systemic delivery of CD4-targeted lentiviral vectors","volume":"195","author":"Zhou","year":"2015","journal-title":"J. Immunol."},{"key":"10.1016\/j.trecan.2026.01.007_bb0110","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1016\/j.ymthe.2020.05.005","article-title":"In vivo generation of CAR T cells selectively in human CD4+ lymphocytes","volume":"28","author":"Agarwal","year":"2020","journal-title":"Mol. Ther."},{"key":"10.1016\/j.trecan.2026.01.007_bb0115","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.201809158","article-title":"In vivo generation of human CD 19- CAR T cells results in B-cell depletion and signs of cytokine release syndrome","volume":"10","author":"Pfeiffer","year":"2018","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.trecan.2026.01.007_bb0120","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2019.1671761","article-title":"In vivo generated human CAR T cells eradicate tumor cells","volume":"8","author":"Agarwal","year":"2019","journal-title":"OncoImmunology"},{"key":"10.1016\/j.trecan.2026.01.007_bb0125","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.omtm.2022.06.004","article-title":"In vivo generation of CAR T cells in the presence of human myeloid cells","volume":"26","author":"Ho","year":"2022","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.trecan.2026.01.007_bb0130","doi-asserted-by":"crossref","first-page":"2769","DOI":"10.1182\/blood-2021-148709","article-title":"In vivo delivery of a CD20 CAR using a CD8-targeted fusosome in southern pig-tail macaques (M. nemestrina) results in B cell depletion","volume":"138","author":"Cunningham","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.trecan.2026.01.007_bb0135","doi-asserted-by":"crossref","first-page":"7121","DOI":"10.1182\/blood-2023-189669","article-title":"Preclinical efficacy of a novel CD8-targeted fusosome for in vivo CAR T cell therapy","volume":"142","author":"Chaturvedi","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.trecan.2026.01.007_bb0140","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1038\/s41592-022-01436-z","article-title":"Antigen identification and high-throughput interaction mapping by reprogramming viral entry","volume":"19","author":"Dobson","year":"2022","journal-title":"Nat. Methods"},{"key":"10.1016\/j.trecan.2026.01.007_bb0145","doi-asserted-by":"crossref","first-page":"5141","DOI":"10.1038\/s41467-023-40788-8","article-title":"Cell type-specific delivery by modular envelope design","volume":"14","author":"Strebinger","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.trecan.2026.01.007_bb0150","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1038\/s41467-018-03432-4","article-title":"Structural basis for the recognition of LDL-receptor family members by VSV glycoprotein","volume":"9","author":"Nikolic","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.trecan.2026.01.007_bb0155","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/S0140-6736(25)01030-X","article-title":"In-vivo B-cell maturation antigen CAR T-cell therapy for relapsed or refractory multiple myeloma","volume":"406","author":"Xu","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.trecan.2026.01.007_bb0160","doi-asserted-by":"crossref","first-page":"4937","DOI":"10.1016\/j.ymthe.2025.06.036","article-title":"Targeted in vivo delivery of genetic medicines utilizing an engineered lentiviral vector platform results in CAR T and NK cell generation","volume":"33","author":"Andorko","year":"2025","journal-title":"Mol. Ther."},{"key":"10.1016\/j.trecan.2026.01.007_bb0165","doi-asserted-by":"crossref","first-page":"LBA-1","DOI":"10.1182\/blood-2025-LBA-1","volume":"146","author":"Harrison","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.trecan.2026.01.007_bb0170","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1038\/mt.2009.282","article-title":"Cocal-pseudotyped lentiviral vectors resist inactivation by human serum and efficiently transduce primate hematopoietic repopulating cells","volume":"18","author":"Trobridge","year":"2010","journal-title":"Mol. Ther."},{"key":"10.1016\/j.trecan.2026.01.007_bb0175","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-006292","article-title":"Preclinical proof of concept for VivoVec, a lentiviral-based platform for in vivo CAR T-cell engineering","volume":"11","author":"Michels","year":"2023","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.trecan.2026.01.007_bb0180","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1182\/blood.2024024523","article-title":"In vivo CAR T-cell generation in nonhuman primates using lentiviral vectors displaying a multidomain fusion ligand","volume":"144","author":"Nicolai","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.trecan.2026.01.007_bb0185","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aav7325","article-title":"Phagocytosis-shielded lentiviral vectors improve liver gene therapy in nonhuman primates","volume":"11","author":"Milani","year":"2019","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.trecan.2026.01.007_bb0190","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.15252\/emmm.201708148","article-title":"Genome editing for scalable production of alloantigen-free lentiviral vectors for in vivo gene therapy","volume":"9","author":"Milani","year":"2017","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.trecan.2026.01.007_bb0195","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1056\/NEJMoa2401361","article-title":"Risk of second tumors and T-cell lymphoma after CAR T-cell therapy","volume":"390","author":"Hamilton","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.trecan.2026.01.007_bb0200","doi-asserted-by":"crossref","first-page":"2479","DOI":"10.1016\/j.ymthe.2025.04.045","article-title":"Current clinical applications of AAV-mediated gene therapy","volume":"33","author":"Byrne","year":"2025","journal-title":"Mol. Ther."},{"key":"10.1016\/j.trecan.2026.01.007_bb0205","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1016\/j.ymthe.2025.03.037","article-title":"The curious case of AAV immunology","volume":"33","author":"Keeler","year":"2025","journal-title":"Mol. Ther."},{"key":"10.1016\/j.trecan.2026.01.007_bb0210","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1038\/s41392-024-01780-w","article-title":"Adeno-associated virus as a delivery vector for gene therapy of human diseases","volume":"9","author":"Wang","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.trecan.2026.01.007_bb0215","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.biomaterials.2017.07.032","article-title":"Covalent coupling of high-affinity ligands to the surface of viral vector particles by protein trans-splicing mediates cell type-specific gene transfer","volume":"144","author":"Muik","year":"2017","journal-title":"Biomaterials"},{"key":"10.1016\/j.trecan.2026.01.007_bb0220","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1089\/hum.1998.9.13-1929","article-title":"Development of novel cell surface CD34-targeted recombinant adenoassociated virus vectors for gene therapy","volume":"9","author":"Yang","year":"1998","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.trecan.2026.01.007_bb0225","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1016\/j.ymthe.2025.03.056","article-title":"Advances in AAV capsid engineering: integrating rational design, directed evolution and machine learning","volume":"33","author":"Nisanov","year":"2025","journal-title":"Mol. Ther."},{"key":"10.1016\/j.trecan.2026.01.007_bb0230","doi-asserted-by":"crossref","first-page":"2801","DOI":"10.1016\/j.ymthe.2024.12.012","article-title":"Tailoring capsid-directed evolution technology for improved AAV-mediated CAR-T generation","volume":"33","author":"Westhaus","year":"2025","journal-title":"Mol. Ther."},{"key":"10.1016\/j.trecan.2026.01.007_bb0235","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1038\/s41408-021-00508-1","article-title":"AAV-mediated in vivo CAR gene therapy for targeting human T-cell leukemia","volume":"11","author":"Nawaz","year":"2021","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.trecan.2026.01.007_bb0240","doi-asserted-by":"crossref","first-page":"3470","DOI":"10.1016\/j.ymthe.2024.08.002","article-title":"T-cell specific in vivo gene delivery with DART-AAVs targeted to CD8","volume":"32","author":"Demircan","year":"2024","journal-title":"Mol. Ther."},{"key":"10.1016\/j.trecan.2026.01.007_bb0245","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1038\/s41587-023-02085-z","article-title":"In vivo human T cell engineering with enveloped delivery vehicles","volume":"42","author":"Hamilton","year":"2024","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.trecan.2026.01.007_bb0250","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/s41573-020-0090-8","article-title":"Engineering precision nanoparticles for drug delivery","volume":"20","author":"Mitchell","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.trecan.2026.01.007_bb0255","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1038\/s12276-023-01086-x","article-title":"Immunogenicity of lipid nanoparticles and its impact on the efficacy of mRNA vaccines and therapeutics","volume":"55","author":"Lee","year":"2023","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/j.trecan.2026.01.007_bb0260","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtm.2025.101436","article-title":"Why do lipid nanoparticles target the liver? Understanding of biodistribution and liver-specific tropism","volume":"33","author":"Hosseini-Kharat","year":"2025","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.trecan.2026.01.007_bb0265","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1038\/s41565-025-01954-9","article-title":"A versatile antibody capture system drives specific in vivo delivery of mRNA-loaded lipid nanoparticles","volume":"20","author":"Chen","year":"2025","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/j.trecan.2026.01.007_bb0270","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2021.121339","article-title":"In situ T-cell transfection by anti-CD3-conjugated lipid nanoparticles leads to T-cell activation, migration, and phenotypic shift","volume":"281","author":"Kheirolomoom","year":"2022","journal-title":"Biomaterials"},{"key":"10.1016\/j.trecan.2026.01.007_bb0275","doi-asserted-by":"crossref","first-page":"3293","DOI":"10.1016\/j.ymthe.2021.06.004","article-title":"Highly efficient CD4+ T cell targeting and genetic recombination using engineered CD4+ cell-homing mRNA-LNPs","volume":"29","author":"Tomb\u00e1cz","year":"2021","journal-title":"Mol. Ther."},{"key":"10.1016\/j.trecan.2026.01.007_bb0280","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1126\/science.abm0594","article-title":"CAR T cells produced in vivo to treat cardiac injury","volume":"375","author":"Rurik","year":"2022","journal-title":"Science"},{"key":"10.1016\/j.trecan.2026.01.007_bb0285","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2025-011759","article-title":"T cell-specific non-viral DNA delivery and in vivo CAR-T generation using targeted lipid nanoparticles","volume":"13","author":"Bimbo","year":"2025","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.trecan.2026.01.007_bb0290","doi-asserted-by":"crossref","DOI":"10.1002\/smll.202304378","article-title":"In vivo mRNA CAR T cell engineering via targeted ionizable lipid nanoparticles with extrahepatic tropism","volume":"20","author":"Billingsley","year":"2024","journal-title":"Small"},{"key":"10.1016\/j.trecan.2026.01.007_bb0295","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1126\/science.ads8473","article-title":"In vivo CAR T cell generation to treat cancer and autoimmune disease","volume":"388","author":"Hunter","year":"2025","journal-title":"Science"},{"key":"10.1016\/j.trecan.2026.01.007_bb0300","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1056\/NEJMc2509522","article-title":"In vivo CD19 CAR T-cell therapy for refractory systemic lupus erythematosus","volume":"393","author":"Wang","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.trecan.2026.01.007_bb0305","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1038\/s41587-022-01494-w","article-title":"Systematic discovery of recombinases for efficient integration of large DNA sequences into the human genome","volume":"41","author":"Durrant","year":"2023","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.trecan.2026.01.007_bb0310","article-title":"Cardiolipin-mimic lipid nanoparticles without antibody modification delivered senolytic in vivo CAR-T therapy for inflamm-aging","volume":"6","author":"Zhang","year":"2025","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.trecan.2026.01.007_bb0315","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1016\/j.ymthe.2021.01.018","article-title":"Circular RNAs: expression, localization, and therapeutic potentials","volume":"29","author":"Yang","year":"2021","journal-title":"Mol. Ther."},{"key":"10.1016\/j.trecan.2026.01.007_bb0320","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1080\/17425247.2020.1796628","article-title":"Poly(beta-amino ester)s as gene delivery vehicles: challenges and opportunities","volume":"17","author":"Karlsson","year":"2020","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.trecan.2026.01.007_bb0325","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/j.omtn.2023.04.019","article-title":"Poly(\u03b2-amino ester)s-based nanovehicles: structural regulation and gene delivery","volume":"32","author":"Zhang","year":"2023","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.trecan.2026.01.007_bb0330","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2024.122896","article-title":"Poly(\u03b2-amino ester) polymer library with monomer variation for mRNA delivery","volume":"314","author":"Kim","year":"2025","journal-title":"Biomaterials"},{"key":"10.1016\/j.trecan.2026.01.007_bb0335","doi-asserted-by":"crossref","first-page":"6983","DOI":"10.1038\/s41467-023-42672-x","article-title":"Charge-altering releasable transporters enhance mRNA delivery in vitro and exhibit in vivo tropism","volume":"14","author":"Li","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.trecan.2026.01.007_bb0340","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1038\/nnano.2017.57","article-title":"In situ programming of leukaemia-specific T cells using synthetic DNA nanocarriers","volume":"12","author":"Smith","year":"2017","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/j.trecan.2026.01.007_bb0345","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.876339","article-title":"Impact of manufacturing procedures on CAR T cell functionality","volume":"13","author":"Watanabe","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.trecan.2026.01.007_bb0350","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.ccell.2022.04.006","article-title":"Regional CAR T cell therapy: an ignition key for systemic immunity in solid tumors","volume":"40","author":"Cherkassky","year":"2022","journal-title":"Cancer Cell"},{"key":"10.1016\/j.trecan.2026.01.007_bb0355","doi-asserted-by":"crossref","first-page":"10218","DOI":"10.1038\/s41467-024-54292-0","article-title":"In vivo gene editing of T-cells in lymph nodes for enhanced cancer immunotherapy","volume":"15","author":"Qu","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.trecan.2026.01.007_bb0360","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1001\/jamaoncol.2023.4504","article-title":"Implications of high tumor burden on chimeric antigen receptor T-cell immunotherapy: a review","volume":"10","author":"Ventin","year":"2024","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.trecan.2026.01.007_bb0365","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtn.2025.102676","article-title":"Preclinical efficacy of multi-targeting mRNA-based CAR T cell therapy in resection models of glioblastoma","volume":"36","author":"Dagher","year":"2025","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.trecan.2026.01.007_bb0370","doi-asserted-by":"crossref","first-page":"3132.1","DOI":"10.1182\/blood-2024-194909","article-title":"ALPHA3, a pivotal phase 2 study of first-line consolidation with cemacabtagene ansegedleucel (Cema-Cel) in patients with large B-cell lymphoma and minimal residual disease after response to standard therapy","volume":"144","author":"Westin","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.trecan.2026.01.007_bb0375","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.omtm.2021.02.013","article-title":"Anti-CD19 CARs displayed at the surface of lentiviral vector particles promote transduction of target-expressing cells","volume":"21","author":"Cordes","year":"2021","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.trecan.2026.01.007_bb0380","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/s41586-021-04390-6","article-title":"Decade-long leukaemia remissions with persistence of CD4+ CAR T cells","volume":"602","author":"Melenhorst","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.trecan.2026.01.007_bb0385","doi-asserted-by":"crossref","first-page":"77.e1","DOI":"10.1016\/j.jtct.2023.10.017","article-title":"Real-world outcomes with chimeric antigen receptor T cell therapies in large B cell lymphoma: a systematic review and meta-analysis","volume":"30","author":"Jacobson","year":"2024","journal-title":"Transplant. Cell. Ther."},{"key":"10.1016\/j.trecan.2026.01.007_bb0390","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1182\/blood.2022015526","article-title":"Efficacy and safety of cilta-cel in patients with progressive multiple myeloma after exposure to other BCMA-targeting agents","volume":"141","author":"Cohen","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.trecan.2026.01.007_bb0395","article-title":"B cell targeting in CAR T cell therapy: side effect or driver of CAR T cell function? Sci","volume":"14","author":"Chen","year":"2022","journal-title":"Transl. Med."},{"key":"10.1016\/j.trecan.2026.01.007_bb0400","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1038\/s41375-025-02585-8","article-title":"Current landscape of vector safety and genotoxicity after hematopoietic stem or immune cell gene therapy","volume":"39","author":"Ottaviano","year":"2025","journal-title":"Leukemia"},{"key":"10.1016\/j.trecan.2026.01.007_bb0405","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1182\/blood.2024024166","article-title":"Second primary malignancies after commercial CAR T-cell therapy: analysis of the FDA adverse events reporting system","volume":"143","author":"Elsallab","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.trecan.2026.01.007_bb0410","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1182\/blood.2024025828","article-title":"T-cell lymphomas in recipients of CAR-T cells: assessing risks and causalities","volume":"144","author":"Hu","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.trecan.2026.01.007_bb0415","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adj6251","article-title":"Enhancing the safety of CAR-T cell therapy: synthetic genetic switch for spatiotemporal control","volume":"10","author":"Lu","year":"2024","journal-title":"Sci. Adv."},{"key":"10.1016\/j.trecan.2026.01.007_bb0420","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.coi.2021.07.002","article-title":"Safety switches for adoptive cell therapy","volume":"74","author":"Sahillioglu","year":"2022","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.trecan.2026.01.007_bb0425","article-title":"Regulation of CAR transgene expression to design semiautonomous CAR-T","volume":"32","author":"G\u0142owacki","year":"2024","journal-title":"Mol. Ther. Oncol."}],"container-title":["Trends in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405803326000075?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405803326000075?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T13:21:21Z","timestamp":1778764881000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405803326000075"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":85,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S2405803326000075"],"URL":"https:\/\/doi.org\/10.1016\/j.trecan.2026.01.007","relation":{},"ISSN":["2405-8033"],"issn-type":[{"value":"2405-8033","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"In vivo CAR T cell engineering: design principles and open questions","name":"articletitle","label":"Article Title"},{"value":"Trends in Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.trecan.2026.01.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}